50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Syndax Pharmaceuticals CMO position eliminated

EditorAhmed Abdulazez Abdulkadir
Published 23/12/2024, 01:58
SNDX
-

WALTHAM, MA – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX), a biopharmaceutical company focused on the development of cancer therapies, disclosed in a recent SEC filing that the company has eliminated the role of Chief Medical (TASE:PMCN) Officer (CMO). Dr. Catherine Madigan, who served as the CMO, will depart from her position effective today.

The company stated that this organizational change is in line with the terms outlined in Dr. Madigan's service agreement. Specific details regarding the severance compensation for Dr. Madigan were referenced in the company's Annual Report on Form 10-K for the fiscal year ending December 31, 2023.

Syndax Pharmaceuticals, incorporated in Delaware and based in Waltham, Massachusetts, is recognized under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations.

The announcement comes without further elaboration on the reasons behind the elimination of the CMO position or the company's future strategic direction in the wake of this change. The information is based on a press release statement.

Syndax's business address remains at 35 Gatehouse Drive, Building D, Floor 3, Waltham, MA 02451, and the company can be reached at the phone number (781) 419-1400.

The filing was made in accordance with the requirements of the Securities Exchange Act of 1934 and was signed by Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.